REFRACTORY CANCER

This study is testing if adding a common heartburn medication (omeprazole) to a standard chemotherapy drug (cabazitaxel) can better control advanced prostate cancer that has stopped responding to other treatments. It will involve about 50 men whose cancer has progressed despite p…

This study is testing a new personalized treatment for adults with advanced solid tumors that have returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to better target their cancer, and then infuse them back. The t…

This study is testing the safety of a new two-drug combination (avutometinib and defactinib) for children and young adults (ages 3-30) whose solid tumors have come back or stopped responding to standard treatments. The main goal is to find the highest dose that is safe and causes…

This is a first-in-human study testing a new experimental drug called 177Lu-SN201 in adults with advanced solid tumors that have progressed despite standard treatments. The drug is a radioactive nanoparticle designed to accumulate in tumors. The main goals are to find a safe and …

This study aims to develop a safe process for giving the drug teclistamab to patients with advanced multiple myeloma in an outpatient or home setting, rather than requiring a hospital stay. It will enroll 15 patients who have tried at least three other treatments, along with thei…

This is the first time a new drug called IMA401 is being tested in people. The main goal is to find a safe dose and see if it can help control advanced solid tumors that have come back or stopped responding to other treatments. The study will test IMA401 by itself and combined wi…

This early-stage trial is testing a new immune therapy drug called ADU-1805, both alone and combined with an existing cancer drug (pembrolizumab). It aims to find safe doses and see if the treatment helps control advanced solid tumors that haven't responded to standard treatments…

This is an early-stage study to find a safe dose of an experimental therapy called MQ710 for people with advanced solid tumors that have returned, spread, or stopped responding to standard treatments. The therapy is a modified virus designed to be injected directly into tumors. R…

This study is testing a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) for adults with primary central nervous system lymphoma (PCNSL) that has returned or not responded to prior treatment. The goal is to see if this combination can control the cancer and st…

This study is testing the safety and early effectiveness of a new drug, BGB-16673, when given with other cancer medicines. It is for people whose B-cell cancers, like certain lymphomas, have returned or stopped responding to previous treatments. The trial will test four different…

This trial is testing a new, first-of-its-kind drug called IMA402 in adults with advanced solid tumors that have come back or stopped responding to all standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll about 1…

This trial aims to find better treatments for children and young adults with advanced cancers that have not responded to standard therapies. It will test personalized combinations of targeted drugs, chosen based on the unique genetic profile of each patient's tumor. The goal is t…

This study is testing whether adding a new drug called epcoritamab to a standard chemotherapy regimen (GDP) is safe and effective for adults whose large B-cell lymphoma has returned or stopped responding to prior treatment. The goal is to control the cancer and see if patients ca…

This study is testing whether combining two drugs, zanubrutinib and pemetrexed, can help control brain lymphomas that have come back or not responded to previous treatments. It will involve about 15 patients to first check safety and then see how well the treatment works to shrin…

This study is testing a new, experimental treatment called CAR-T cell therapy for people with head and neck cancer that has come back or stopped responding to standard treatments. The main goals are to find a safe dose and see what side effects occur. Researchers will collect a p…